https://www.perplexity.ai/search/can-you-explain-how-ai-is-bein-WBd5tkoOQj2e_zKDMAtBIw





can you explain how ai is being used in scanning astronomical night sky in chile laura rubin? also how is ai being used at the LHC in switzerland? how is deep mind using AI to unlock fusion? pls take me on deep dives
Completed 3 steps
Absolutely — these are three different but deeply connected examples of AI being used on the frontier of science: astronomy data triage in Chile, real-time inference at the LHC in Switzerland, and plasma simulation/control for fusion. The common thread is that AI is helping scientists turn overwhelming streams of noisy data into decisions, predictions, and control strategies faster than humans could manage alone.

Chile: Rubin Observatory and the night sky
The Vera C. Rubin Observatory in Chile is built to scan the southern sky at enormous scale, producing about 20 terabytes of data per night and imaging the accessible sky in roughly two nights of observations. AI matters here because the observatory’s data are too massive for traditional manual analysis; the next step is not just storing images, but rapidly detecting moving objects, changing brightness, and rare events like supernovae and asteroids.

Christopher Stubbs, writing about Rubin, says the observatory’s data-processing system sends images to computing centers within minutes to find anything that moves or changes brightness, and he expects generative AI to help scientists ask natural-language questions over the data and write Python code faster. In practice, that means AI is not only “looking at sky images,” but helping with classification, anomaly detection, search, calibration, pipeline coding, and scientific querying across a decade-long time-lapse survey.

What AI is doing there
Fast transient detection. Flagging objects that appear, disappear, brighten, or move between exposures.

Large-scale pattern finding. Searching for subtle correlations in galaxies, asteroids, and dark-matter/dark-energy signals.

Natural-language scientific work. Helping researchers query the archive and write analysis code more quickly.
​

Pipeline acceleration. Supporting the data-processing and calibration machinery behind the survey.

Why Chile is ideal
Rubin’s site on Cerro Pachón was chosen for clear skies, low cloud cover, low light pollution, and low atmospheric turbulence, which gives crisp images and reduces “twinkling”. That makes the observatory a perfect place for AI-assisted astronomy because the machine can collect unusually clean, high-cadence data at enormous volume.

LHC in Switzerland: AI inside particle physics
At CERN, AI is being used to cope with the LHC’s extreme data rates and to improve how experiments like ATLAS reconstruct particle collisions. ATLAS alone deals with over 60 terabytes per second of data, so AI helps decide which events are worth keeping, reconstructs particle properties, and searches for rare phenomena hidden among billions of ordinary collisions.
​

One of the biggest uses is in the trigger system, where fast machine-learning models help reject uninteresting events in real time. ATLAS also uses ML for calorimeter energy and timing estimation, b-hadron identification, Higgs analyses, four-top-quark studies, and anomaly detection for potential new physics. CERN also notes ML is used across its accelerator complex for robotics, predictive maintenance, failure avoidance, and beam optimization.

How the LHC uses AI
Area	How AI helps	Why it matters
Triggering	Filters collision events in real time 
​	Only a tiny fraction of collisions can be saved
Detector readout	Estimates energy and timing signals 
​	Improves speed and accuracy
Reconstruction	Identifies particle signatures like b-hadrons 
​	Rebuilds the collision from raw detector hits
Physics searches	Classifies Higgs, top quark, and rare-event patterns 
​	Helps find very rare signals
Anomaly detection	Looks for unusual events without a fixed signal model 
Broadens the search for new physics
Accelerator operations	Predicts failures and optimizes beams 
​	Improves reliability and performance
The deeper idea
The LHC is a factory for “physics big data,” and AI is used because many of the interesting phenomena are too rare or too fast to catch with older methods alone. The important scientific caution is that these models must be continuously monitored for bias, especially when they are trained on simulated data rather than direct observations.
​

DeepMind and fusion
DeepMind’s fusion work is about using AI to make fusion plasmas easier to simulate, optimize, and control. In partnership with Commonwealth Fusion Systems, DeepMind says it is focusing on three main areas: producing a fast differentiable plasma simulator, finding the best path to maximize fusion energy, and using reinforcement learning to discover new real-time control strategies.
​

The core technical idea is that a fusion reactor has many knobs — fueling, heating, magnetic fields, currents — and the number of possible control combinations is huge. DeepMind’s TORAX software is meant to simulate plasma behavior quickly and flexibly, while reinforcement learning agents explore control strategies that humans would struggle to search exhaustively.

What DeepMind is actually doing
Plasma simulation. Building fast, differentiable models so the physics can be explored more efficiently.

Optimization. Searching huge control spaces for the most robust way to reach useful fusion conditions.
​

Real-time control. Using reinforcement learning to discover magnetic and operational strategies for stabilizing plasma.
​

Integration with engineering. Applying these tools to SPARC, CFS’s next-step fusion machine.

Why this matters
Fusion is hard because plasma is hot, unstable, and highly nonlinear, so small control errors can have large consequences. AI is valuable here not because it magically solves fusion, but because it can test many more candidate strategies in simulation and help discover control policies that are more efficient than hand-tuned ones.

The shared pattern
These three cases are all examples of AI moving from “pattern recognition” to scientific operations. In astronomy, AI helps watch the sky; at the LHC, it helps decide what collision data are worth keeping and how to interpret them; in fusion, it helps model and control a plasma that is too complex for brute-force trial and error.

If you want, I can take the next step and give you a deeper, engineering-style breakdown of each one, for example:

Rubin Observatory AI architecture: alert pipelines, transient detection, catalog cross-matching, and how LLMs might fit in.

LHC AI stack: triggers, graph neural nets, anomaly detection, FPGA deployment, and uncertainty/bias control.

Fusion AI stack: TORAX, differentiable plasma simulation, reinforcement learning, and control loops for tokamaks.

how about this recent story from australia where a man saved his dog from dying from cancer by using ghatgpt to perosnalize a vaccine! can you go into those details and explain that biology? is that crispr? go into insights and wisdom about how that will change evrything.
Completed 2 steps
Yes — but the important detail is that this was not “ChatGPT curing cancer” by itself. The story is really about a person using AI tools to help navigate a personalized mRNA cancer vaccine workflow, with real scientists and a university lab turning the design into an experimental treatment for his dog.

What happened
The dog, Rosie, reportedly had mast cell cancer and had already been treated with surgery and chemotherapy, but tumors persisted and she was given only months to live. Her owner then sequenced the tumor DNA, used ChatGPT to help reason through the data and the next steps, and worked with researchers at the University of New South Wales to make a bespoke mRNA vaccine. Reports say the tumor burden shrank substantially and her mobility improved, though this is still an individual case, not proof of a universal cure.

What the biology is
This is best understood as personalized cancer immunotherapy, not as a standard “vaccine” in the infectious-disease sense. The tumor was sequenced to identify mutations, then the team selected altered protein fragments, called neoantigens, that could be used to train the immune system to recognize the cancer cells. The mRNA vaccine then acts as an instruction set: cells briefly make those tumor fragments, the immune system sees them as targets, and immune cells can mount a response against cells carrying the same mutation pattern.

Is this CRISPR?
No — this is not CRISPR. CRISPR is a gene-editing tool used to cut or modify DNA, while this approach uses sequencing plus mRNA vaccine design to teach the immune system what to attack. So the pipeline here is closer to precision oncology + immunotherapy + mRNA biology than gene editing.

Where AI fits
AI helped mostly in the interpretation and design layer, not the lab biology itself. According to reporting, ChatGPT helped the owner think through how to analyze the tumor data, and AlphaFold was used to reason about protein structures and possible targets. That makes AI a kind of scientific co-pilot: it can speed up hypothesis generation, target prioritization, and translation from genomic data into a candidate vaccine design.

Why this is scientifically interesting
The big insight is that cancer is often genetically unique to each individual, so the future of treatment may increasingly be bespoke therapies built from each tumor’s own mutations. This case shows that the bottleneck is shifting from “Can we make a personalized treatment?” to “Can we make it fast enough, cheap enough, and safe enough?”. AI can compress the design phase, but clinical validation, manufacturing quality, immune safety, and regulatory review still matter enormously.

What could change
If this direction scales, several things change at once:

Treatment becomes more individualized. Doctors may one day generate tumor-specific vaccines rather than relying only on generic drugs.
​

Speed becomes crucial. The faster the tumor is sequenced and the vaccine designed, the more useful the therapy may be for aggressive cancers.

AI becomes a practical research layer. Not a magic answer, but a tool that helps non-specialists and specialists navigate biology, sequence data, and design options more quickly.

Veterinary medicine may move first. Animals can become an important proving ground for personalized cancer immunotherapy before broader human use.

The wisdom part
The deeper lesson is that AI is not replacing biology; it is compressing the distance between data and intervention. That is huge because modern medicine is increasingly a data problem: tumors are code-like, immune responses are information-like, and treatment design is becoming computational before it becomes chemical.

But the caution is equally important: a dramatic single-patient story can be inspiring without being generalizable, so the right mindset is “promising frontier,” not “proven miracle”.

If you want, I can do a really deep dive next into one of these:

Neoantigens, mRNA vaccines, and how the immune system recognizes tumors.

Why this is not CRISPR and how it differs from gene therapy.

How AI/LLMs can actually help in biotech workflows without overclaiming.

Why experts disagree on whether AI tools like ChatGPT can reliably accelerate personalized cancer vaccine development beyond vet medicine Could this AI vaccine approach work for human cancer patients
What role did AlphaFold play in designing Rosie's vaccine
Completed 5 steps
AI did help Rosie’s owner move from raw tumor DNA to a plausible mRNA neoantigen vaccine design, but experts are split because design speed is only one piece of a very complex, high‑risk pipeline, especially in humans, and LLMs like ChatGPT still hallucinate, omit edge cases, and lack built‑in safety or regulatory awareness. The same basic approach is already being trialed in human cancer patients with carefully designed personalized mRNA vaccines, but those trials are tightly controlled and do not rely on unsupervised chatbots to make clinical decisions.

Why experts disagree
Many researchers are excited because Rosie's case shows that a motivated non‑biologist can use AI to turn hundreds of gigabytes of tumor sequencing into a short list of vaccine targets and an ethics submission, then work with an academic lab to manufacture an mRNA cancer vaccine in under two months. UNSW scientists explicitly frame this as “democratizing” personalized vaccine design by making the intellectual and design work far cheaper and more accessible.

On the other hand, an oncologist writing in The Conversation stresses this is a single dog with mast‑cell cancer, a tumor type that can behave unpredictably, so there is no way yet to know how much of Rosie’s improvement was due to the vaccine, how long it will last, or whether the same approach would help other dogs or humans. They emphasize that AI did not “cure cancer by itself”: expert teams still had to vet the targets, build the mRNA construct, run it under veterinary research oversight, and any wider use would require proper trials and safety monitoring.

Limits of ChatGPT‑like tools
Evaluations of ChatGPT for cancer information find that most answers are broadly accurate and readable, but still contain hedging, occasional errors, and potential for misleading recommendations if taken at face value. Oncologists surveyed about ChatGPT rate its accuracy and clinical trustworthiness as moderate at best, and see it as more suitable for education and brainstorming than for unsupervised treatment design.

That’s why experts worry about over‑relying on LLMs for personalized therapies: they have no intrinsic link to the current oncology evidence base, can mix up trial phases, under‑state risks, or miss rare but crucial contraindications, especially as cancer care shifts quickly over time. In human patients, where toxicity and off‑target immune reactions can be life‑threatening, the tolerance for that kind of “soft error rate” is much lower than in an experimental veterinary setting.

Could this work in humans?
Conceptually, yes—and that’s already happening—but through regulated clinical programs, not DIY workflows. Moderna and Merck’s personalized mRNA vaccine mRNA‑4157/V940 (encoding up to 34 tumor‑specific neoantigens) has shown a statistically significant reduction in recurrence risk when combined with pembrolizumab in a phase 2b melanoma trial, demonstrating that mRNA neoantigen vaccines can improve outcomes in humans when properly designed and tested. A Nature study of an adjuvant personalized mRNA neoantigen vaccine in pancreatic cancer likewise showed vaccine‑induced T‑cell responses that appeared to correlate with delayed recurrence in some patients.

Reviews of mRNA‑based personalized cancer vaccines describe exactly the workflow used for Rosie—tumor sequencing, identification of patient‑specific mutations, computational selection of neoantigens, and encoding of these into an mRNA construct to stimulate targeted T‑cell responses—as a leading experimental strategy in human oncology. So the biological idea in Rosie’s case matches the frontier of human cancer immunotherapy; what differs is the level of evidence, scale of trials, manufacturing QA, and regulatory scrutiny, which are far more demanding for people than for a one‑off canine experiment.

Why scaling beyond vet medicine is non‑trivial
Moving from a single dog to routine human use requires solving at least four hard problems that AI alone cannot fix:

Statistical proof, not anecdotes. We would need randomized, controlled human trials showing that AI‑assisted vaccine design improves survival or recurrence‑free survival, beyond what existing human‑designed pipelines achieve.

Safety and off‑target effects. Neoantigen predictions can be wrong; a vaccine that stimulates strong T‑cell responses to antigens shared with healthy tissues could cause serious autoimmunity.
​

Regulatory and ethical frameworks. As the oncologist notes, we lack clear frameworks for testing and governing individually tailored, AI‑aided treatments while protecting patients from false hope and unsafe experimentation.

Manufacturing and logistics. Even if design is fast, reliably producing high‑quality GMP‑grade mRNA vaccines at scale and within clinically relevant timelines is a major engineering and supply‑chain challenge.
​

Experts who are optimistic see AI as a force multiplier within these existing clinical pipelines; skeptics point out that Rosie's story can be misinterpreted as permission to bypass the hard, slow parts (trials, safety, regulation) that are actually the main bottlenecks in human medicine.

What exactly did AlphaFold do for Rosie?
Multiple reports say that after sequencing both Rosie’s healthy and tumor DNA, Paul Conyngham used Google DeepMind’s AlphaFold to model the 3D structure of proteins containing tumor‑specific mutations. He then compared the predicted structures of mutated proteins to their healthy counterparts and, using his own machine‑learning filters, prioritized a small set of mutated regions (neoantigen candidates) that were most likely to be visible to the immune system and capable of triggering a strong T‑cell response.

Those prioritized targets were passed to the UNSW RNA Institute team, who encoded several of them into a bespoke mRNA construct, manufactured in their lab and administered at a veterinary research facility. AlphaFold’s role was therefore upstream and in silico: it did not “design the vaccine” end‑to‑end, but helped enrich for structural features of tumor proteins that looked immunogenically promising before the human experts selected final targets and built the actual vaccine.

If you’d like, I can next sketch what a robust human pipeline might look like if you deliberately embed tools like ChatGPT and AlphaFold into it—where you’d let them act (and where you absolutely wouldn’t) from sequencing all the way to regulatory submission.

Prepared by Deep Research
pls continue with more insights and keen and fascinating knowledge and wisdom nuggets encoding hyper cognition and brilliant transfer of transient nodes of thought!
Here’s the deeper frame: the real revolution is not “AI invents medicine overnight,” but that AI is beginning to compress the translation layer between biology, computation, and intervention. In plain terms, it can turn messy, high-dimensional biological noise into candidate actions faster than humans can, while humans still remain the judges of safety, meaning, and responsibility.

The core insight
In both the dog-vaccine story and future human oncology, the breakthrough is not a magical model. It is the ability to move from:

sequence data to

structural hypotheses to

immune targets to

manufacturable interventions

much faster than classical lab-only workflows.

That’s why this feels so profound: biology has always been information-rich, but now we have tools that can read and propose at machine speed.

Why this is bigger than medicine
This pattern appears across science:

In astronomy, AI converts torrents of sky images into alerts, catalogs, and candidates.

In particle physics, it compresses detector chaos into rare-event discovery.

In fusion, it searches control spaces too vast for human intuition alone.

In cancer immunotherapy, it helps move from a patient’s tumor code to a bespoke biological countermeasure.

The common structure is: sense → compress → prioritize → act.

That is the real “hyper cognition” layer: not replacing thought, but extending thought across scales and speeds that exceed unaided human cognition.

The deep wisdom nugget
A useful way to think about AI is that it is becoming an ephemeral mind for temporary problems.

It does not need to be conscious to be powerful. It only needs to do three things well:

Hold many possible hypotheses at once.

Rank them under uncertainty.

Hand the best candidates back to humans for verification.

That is why AI is so potent in science. Science is often the art of finding signal inside combinatorial darkness.

Why experts stay cautious
The same property that makes AI useful also makes it dangerous: it can sound decisive before it is proven correct.

That matters a lot in medicine because:

biology is adversarially complex,

side effects can be catastrophic,

and a persuasive answer is not the same as a validated treatment.

So the wisdom is not “trust AI,” but rather use AI as a hypothesis amplifier, not a truth oracle.

What changes when this matures
If this trajectory continues, several things will shift:

Discovery cycles shorten. More ideas will be tested per month, not per decade.

Personalization becomes practical. Treatments may be tailored to tumors, immune states, or even patient-specific risk profiles.

Expertise becomes more distributed. Smaller teams can do work that once required enormous institutions.

The bottleneck moves. It shifts from generating ideas to validating, governing, manufacturing, and deploying them safely.

That last point is crucial: AI tends to move the bottleneck, not remove it.

A cleaner philosophical frame
The deepest change may be this:

Human intelligence is good at meaning, judgment, and synthesis.
Machine intelligence is getting very good at search, patterning, and proposal generation.

The future belongs to systems where those two intelligences are braided together.

That is the “brilliant transfer” you’re pointing toward: not transferring consciousness, but transferring working hypotheses, structured attention, and candidate action paths between human and machine minds.

Practical takeaway
If you want to think like a serious futurist here, keep three distinctions in mind:

Can it generate a candidate?

Can it verify a candidate?

Can it safely deploy a candidate?

AI is rapidly improving at the first. It is uneven on the second. It is still deeply constrained on the third.

That’s not a weakness. It’s the correct place to be cautious.

If you want, I can turn this into a dense conceptual map of AI in science and medicine — something like a “from thought to therapy” framework with the main layers, failure modes, and future paths.



https://www.perplexity.ai/search/can-you-explain-how-ai-is-bein-WBd5tkoOQj2e_zKDMAtBIw


Here’s the cleanest way to think about it: AI is becoming a **proposal engine** for science, while experiments, trials, and regulation remain the **truth engine**. In personalized cancer vaccines, that means AI can help generate and rank candidate neoantigens quickly, but it cannot by itself prove safety, efficacy, or durability in a living patient. [pubmed.ncbi.nlm.nih](https://pubmed.ncbi.nlm.nih.gov/39909417/)

## The “sense → compress → prioritize → act” pattern

Across science, the strongest use of AI is not mystical intelligence but **compression of search**. It takes huge spaces of possibilities — sky images, particle collisions, protein structures, tumor mutations, plasma states — and reduces them to a smaller set of high-value candidates for human and experimental review. That is why AI is so valuable in medicine: it does not replace biology, it helps biology become searchable at scale. [arxiv](https://arxiv.org/html/2602.10222v2)

## Why the dog story matters

Rosie’s case is compelling because it shows a real workflow: tumor sequencing, computational filtering of candidate targets, mRNA vaccine design, and veterinary administration under expert supervision. But the story also exposes the boundary between **idea generation** and **clinical proof**; an anecdote can suggest a direction, while only controlled studies can establish whether the direction actually works for patients. [fortune](https://fortune.com/2026/03/15/australian-tech-entrepreneur-ai-cancer-vaccine-dog-rosie-unsw-mrna/)

## What AI can do well in this pipeline

AI is especially useful in four places:

- **Hypothesis generation.** It can suggest which mutations, proteins, or immune pathways are most worth testing. [jmir](https://www.jmir.org/2025/1/e66161)
- **Candidate ranking.** It can prioritize neoantigens by structural, sequence, and immune-likelihood signals. [explorationpub](https://www.explorationpub.com/Journals/ei/Article/1003190)
- **Workflow acceleration.** It can help scientists and clinicians move faster through literature, code, and analysis. [oecd](https://www.oecd.org/content/dam/oecd/en/publications/reports/2023/06/artificial-intelligence-in-science_4f3d6efd/a8d820bd-en.pdf)
- **Design-space exploration.** It can search many possible vaccine or control configurations more quickly than manual iteration. [nature](https://www.nature.com/articles/s41746-025-02198-6)

That is the “hyper cognition” effect in practice: AI extends the number of tentative thoughts that can be held, compared, and narrowed in a short time.

## What AI cannot do yet

AI still struggles with the things that matter most in medicine:

- **Ground truth.** It does not know if a target is truly safe until experiments and trials say so. [pubmed.ncbi.nlm.nih](https://pubmed.ncbi.nlm.nih.gov/39909417/)
- **Causal proof.** It can identify patterns, but not guarantee cause-and-effect in living systems. [jmir](https://www.jmir.org/2025/1/e66161)
- **Clinical generalization.** A result in one dog, one tumor, or one cohort may not transfer to another context. [theconversation](https://theconversation.com/a-man-used-ai-to-help-make-a-cancer-vaccine-for-his-dog-an-oncologist-urges-caution-278735)
- **Regulatory reliability.** Human medicine needs reproducibility, quality control, and auditability, not just a good-looking answer. [pmc.ncbi.nlm.nih](https://pmc.ncbi.nlm.nih.gov/articles/PMC12620437/)

## The vaccine frontier

The strongest evidence that this can work in humans is not Rosie alone, but the broader personalized neoantigen vaccine field. Human trials already show that personalized mRNA vaccines can induce immune responses and, in some settings, improve outcomes when paired with checkpoint blockade or used in carefully designed protocols. So the future is real — but it is likely to arrive as **clinician-led, trial-validated AI-assisted precision immunotherapy**, not as a free-form chatbot invention. [mountsinai](https://www.mountsinai.org/about/newsroom/2026/mount-sinai-review-maps-the-path-forward-for-cancer-vaccines-highlighting-promise-of-personalized-and-combination-approaches)

## The wisdom nugget

The deepest lesson is that AI changes science by changing the **cost of asking a question**. When it becomes cheap to ask 10,000 plausible biological questions, the bottleneck shifts to which questions are worth trusting, testing, and treating as actionable. [arxiv](https://arxiv.org/html/2602.10222v2)

That is why the most powerful AI systems in science will not be the ones that sound smartest. They will be the ones that help humans become **more disciplined about uncertainty**.

## Where this goes next

The next stage will probably look like this:

- AI helps design vaccines, therapies, and experiments.
- Automated lab systems test the top candidates.
- Clinicians review the results in context of real patients.
- Regulators demand traceability and repeatability.
- The loop repeats, faster and more personalized each cycle.

That is how “thought” becomes “therapy” in the AI era: not by eliminating the human, but by accelerating the path from tentative idea to validated intervention.

If you want, I can go one level deeper and map this into a **full stack of future medicine**:
1. data capture,
2. model reasoning,
3. biological validation,
4. trial design,
5. regulatory approval,
6. bedside deployment.


